Back to Journals » ImmunoTargets and Therapy » Volume 10

Current Insights into Immunotherapy Approaches for Food Allergy

Authors Macdougall JD, Burks AW, Kim EH

Received 26 October 2020

Accepted for publication 13 January 2021

Published 27 January 2021 Volume 2021:10 Pages 1—8

DOI https://doi.org/10.2147/ITT.S266257

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 3

Editor who approved publication: Professor Michael Shurin


Jessica D Macdougall,1 A Wesley Burks,1 Edwin H Kim2

1Department of Pediatrics, University of North Carolina School of Medicine, Chapel Hill, NC, USA; 2Department of Medicine, University of North Carolina School of Medicine, Chapel Hill, NC, USA

Correspondence: Edwin H Kim
Department of Medicine, University of North Carolina School of Medicine, 3004 Mary Ellen Jones Building, 116 Manning Dr, CB 8035, Chapel Hill, NC 27599, USA
Tel +1 919 537 3193
Fax +1 919 962 5478
Email edwinkim@email.unc.edu

Abstract: In the last decade, there has been increasing research dedicated to food immunotherapy to induce clinical desensitization and provide protection by increasing clinical reaction thresholds. Results from recent food immunotherapy studies with differing routes of administration (oral, sublingual, and epicutaneous) suggest that food immunotherapy can induce clinical desensitization with varying levels of safety, however lasting tolerance has not been demonstrated. Furthermore, treatment side effects and dosing logistics may make the therapies difficult for some supporting the need for alternative treatment approaches. Peptide immunotherapy and DNA vaccine approaches should in theory allow for safer administration by decreasing allergenicity but proof of their clinical efficacy and immunogenicity remains to be proven. Biologic agents may allow for increased safety and rapid up-dosing of immunotherapy with the added benefit of treating multiple allergens simultaneously.

Keywords: food allergy, oral immunotherapy, sublingual immunotherapy, epicutaneous immunotherapy, omalizumab, dupilumab

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]